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Abstract Palmitoylethanolamide (PEA) is an endogenous
lipid mediator known to reduce pain and inflammation.
However, only limited clinical studies have evaluated the ef-
fects of PEA in neuroinflammatory and neurodegenerative
diseases. Multiple sclerosis (MS) is a chronic autoimmune
and inflammatory disease of the central nervous system.
Although subcutaneous administration of interferon
(IFN)-β1a is approved as first-line therapy for the treatment
of relapsing–remitting MS (RR-MS), its commonly reported
adverse events (AEs) such as pain, myalgia, and erythema at
the injection site, deeply affect the quality of life (QoL) of
patients with MS. In this randomized, double-blind, placebo-
controlled study, we tested the effect of ultramicronized PEA
(um-PEA) added to IFN-β1a in the treatment of clinically
defined RR-MS. The primary objectives were to estimate
whether, with um-PEA treatment, patients with MS perceived
an improvement in pain and a decrease of the erythema width
at the IFN-β1a injection site in addition to an improvement in
their QoL. The secondary objectives were to evaluate the ef-
fects of um-PEA on circulating interferon-γ, tumor necrosis
factor-α, and interleukin-17 serum levels, N-acylethanolamine
plasma levels, Expanded Disability Status Scale (EDSS) pro-
gression, and safety and tolerability after 1 year of treatment.
Patients with MS receiving um-PEA perceived an improve-
ment in pain sensation without a reduction of the erythema at
the injection site. A significant improvement in QoL was ob-
served. No significant difference was reported in EDSS score,
and um-PEA was well tolerated. We found a significant
increase of palmitoylethanolamide, anandamide and
oleoylethanolamide plasma levels, and a significant reduction
of interferon-γ, tumor necrosis factor-α, and interleukin-17 se-
rum profile compared with the placebo group. Our results sug-
gest that um-PEA may be considered as an appropriate add-on
therapy for the treatment of IFN-β1a-related adverse effects in
RR-MS.
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Introduction
Palmitoylethanolamide (PEA) is an endogenous lipid media-
tor and a member of the N-acylethanolamine (NAE) family of
bioactive lipids. PEA is present in the central nervous system
(CNS) [1]; however, its exact role in the CNS during
neuroinflammatory processes remains to be fully understood.
Since the 1990s, interest in the therapeutic potential of PEA
has increased owing to the discovery of the effects of PEA in
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many preclinical paradigms for pain and chronic inflamma-
tion [2]. PEA has antinociceptive properties in several animal
models [3–5], prevents neurotoxicity and neurodegeneration
[6–8], and inhibits peripheral inflammation and mast cell de-
granulation [9, 10]. These effects of PEA are not only ob-
served when used as a drug (i.e., after direct administration)
[11, 12], but also when its endogenous levels are increased by
blocking its catabolism [13]. Although the receptors mediat-
ing the effects of PEA are not fully characterized, its anti-
inflammatory effects have been associated with peroxi-
some proliferator-activated receptor-α (PPAR-α) activa-
tion [11, 14, 15].
Multiple sclerosis (MS) is a chronic idiopathic disorder of
the CNS sustained by a multifocal inflammatory process in-
volving both the white and gray matters [16–18]. Although
there are several forms of MS, during the initial phases of the
disease a large proportion of patients present a relapsing–re-
mitting (RR) clinical form of the disease (RR-
MS). Currently, various disease-modifying drugs are indicated
as first-line therapy for RR-MS. These include glatiramer ac-
etate, interferon (IFN)-β1b and IFN-β1a, which are all widely
used as first-line disease-modifying drugs [19–23]. However,
their subcutaneous injection is hindered by possible local and
systemic adverse effects (injection site pain, burning, myalgia,
erythema, and necrosis) that affect patient compliance and
thus efficacy [24–26].
The analgesic and anti-inflammatory properties of PEA
make it an ideal candidate as adjuvant therapy to reduce the
side effects of the immunomodulatory drugs available for
RR-MS. Moreover, PEA was shown to reduce immune cells
activation and proinflammatory cytokine expression in the
CNS of mice with virus-induced MS [27]. Therefore, PEA
could act by cooperating with immunomodulatory drugs and
increase their efficacy in reducing pain and inflammation inMS.
Thus, the aim of the present study was to evaluate the oral
administration of ultramicronized PEA (um-PEA) as an add-
on therapy for RR-MS in reducing the IFN-β1a-related side
effects, as well as the safety and tolerability of this adjuvant
treatment.
Patients and Methods
Study Population
Twenty-nine patients (17 men, 12 women; mean±SD age 27
± 8 years) affected by definite RR-MS according to
McDonald’s 2010 criteria [28], who were treated with subcu-
taneous IFN-β1a for at least 6 months and were experiencing
IFN-β1a-related AEs, were enrolled at the Department of
Neurosciences, Reproductive and Odontostomatological
Sciences, Federico II University of Naples, Italy, from
January 2011 to April 2011. Inclusion criteria were: definite
diagnosis of RR-MS, age between 18 and 55 years, disease
duration of<1 year, and an Expanded Disability Status Scale
(EDSS) score between 1.0 and 3.5. The exclusion criteria
were: MS-related conditions, such as current clinical relapse
(defined as newly developing symptoms or reactivation of
pre-existing deficits for a minimum of 24 h occurring at least
30 days after the preceding episode, in the absence of in-
creased body temperature or infections) [28], steroid therapy
30 days prior to study entry, concomitant diseases precluding
the IFN-β1a treatment; pregnancy or breastfeeding, cognitive
decline preventing informed consent, pathological conditions
interfering withMS evolution, nonsteroidal anti-inflammatory
drugs allergy, or intolerance to IFN-β1a. This study was ap-
proved by the institutional ethics committee for biomedical
activities "Carlo Romano" Medical School Federico II
University, Naples, Italy (registration number 197/2011), and
all patients gave their written informed consent. The study was
performed in compliance with the good clinical practice
guidelines and the principles of the Declaration of Helsinki.
Experimental Design
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This was a double-blind, randomized, placebo-controlled
study. After the screening period, eligible patients were ran-
domized 1:1 to receive ultramicronized PEA (um-PEA)
(NORMAST® 600 mg/day/p.o.) or placebo, both added to
subcutaneous IFN-β1a (Rebif® 44 μg; 3 times a week)
administered using a prefilled syringe, for 12 months.
Randomization was performed at our study center using kit
numbers as randomization numbers. The study medication,
um-PEA and placebo, were provided by Epitech Group SpA
(Saccolongo, Italy) in the form of um-PEA or placebo-
containing pills. All the pill containers were sequentially num-
bered, tamper-proof, equal in weight, and similar in appear-
ance. All the patients enrolled in the study were blind to the
treatment (PEA or placebo). All patients underwent a full neu-
rological examination by a single neurologist during the
screening phase and after 1, 6, and 12 months of treatment.
This examination included: 1) the evaluation of motor disabil-
ity using the EDSS [29]; 2) evaluation of quality of life (QoL)
by the Multiple Sclerosis Quality of Life-54 questionnaire
(MSQoL-54) (developed by combining the most widely uti-
lized generic measure of quality of life in the world, the Short
Form-36, with additional items specific to MS) [30]; 3) paced
auditory serial addition test (PASAT) (a measure of cognitive
function that assesses auditory information processing speed
and flexibility, as well as calculation ability) [31, 32]; and 4)
the assessment of pain using a visual analog scale (VAS) [gen-
erally presented as a single line of 100 mm with anchor words
at either end (e.g., no pain to worst possible pain)] [33]. The
width (in mm) of the erythema induced by IFN-β1a at its
injection site was evaluated over its maximum diameter at
1 month, and after 6 and 12 months of PEA or placebo
treatment. Blood samples were collected from all the patients
to quantify NAE plasma levels (1, 3, 6, 9, and 12 months) and
proinflammatory cytokines (1, 3, 6, and 12 months). The pri-
mary endpoints of the study were to evaluate the efficacy of
um-PEA in 1) reducing IFN-β1a-related adverse effects in
patients with RR-MS (pain and erythema width at the injec-
tion site); and 2) improving the patients’ QoL. The secondary
endpoints were to evaluate the effects of um-PEA on 1) the
serum profile of the proinflammatory cytokines IFN-γ, tumor
necrosis factor-α (TNF-α), and interleukin (IL)-17; 2) the
plasma levels of PEA, oleoylethanolamide (OEA), and the
endocannabinoid anandamide (AEA); 3) clinical disease pro-
gression (sustained disability progression is clinically defined
as at least a 1-point increase from baseline EDSS score); and
4) on safety and tolerability of um-PEA.
Quantification of the NAE plasma levels
Blood (4ml) was collected in ethylenediaminetetraacetic acid-
containing tubes (Becton Dickinson, Oxford, UK) on ice, and
centrifuged (10 min; 4 °C; 2000×g) within 1 h of collection.
Aliquots (0.5 ml) of plasma were transferred into 1.5-ml tubes
(Eppendorf, Hamburg, Germany) and immediately stored at –
80 °C until assay. Only samples without evidence of hemoly-
sis were used. For NAE extraction from plasma, we trans-
ferred 250 μl of plasma into a Sovirel tube containing the
internal standards [d4-PEA (50 ng/ml), d4-OEA (50 ng/mL),
and d4-AEA (10 ng/mL); all Cayman Europe, Tallinn,
Estonia]. 2 ml of ethyl acetate-hexane (9:1, v/v) was then
added and the mixture extracted for 30 min before centrifuga-
tion (2000×g, 15 min). The organic layer was recovered and
evaporated, in part, under N2 at 40 °C. The residual organic
phase was transferred to a microvial and subsequently evapo-
rated under N2 at 40 °C. The residue was finally reconstituted
in 200 μl acetonitrile. The samples (8 μl) were analyzed by
ultra performance liquid chromatography (UPLC)/tandem
mass spectrometry using an Acquity UPLC system (Waters,
Etten-Leur, the Netherlands) coupled to a TQD mass spec-
trometer (Waters) controlled by MassLinkx. Analyte separa-
tion was performed on a reverse-phase C18 column (Restek
100 mm×2.1 mm i.d., 1.9 μm particle size) and a precolumn
(Restek Ultra C18 10 mm×2.1 mm i.d.) maintained at 40 °C
with a mobile phase flow rate of 0.2 ml/min. Mobile phase A
consisted of 10mMammonium formate in UPLC-grade water
and 0.1 % (v/v) formic acid. Mobile phase Bwas UPLC-grade
acetonitrile (Sigma-Aldrich, Milan, Italy) containing 0.1 %
(v/v) formic acid. The total run time was 5 min. Electrospray
ionization was carried out in the positive mode using nitrogen
as the nebulizing gas. MS parameters for all analyses were
established by infusing standards (100 ng/ml) using an infu-
sion pump. The multiple reaction-monitoring modes were
employed for quantification. Mass spectrometric parameters
used for the analysis of AEA, PEA, and OEA are summarized
in Supplementary Table 1 (Supplementary methods). The se-
lected transitions for the quantitative measurements were as
follows: AEA = 348.3→ 62.1; d4-AEA = 352.3→ 66.0;
P EA = 3 0 0 . 3 → 6 2 . 0 ; d 4 - P EA = 3 0 4 . 3 → 6 2 . 0 ;
OEA=326.3→ 62.1; d4-OEA=330.3→66.0. The calibra-
tion curves were constructed using linear regressions between
the peak area ratios of each compound relative to the internal
standard and the corresponding concentrations. Linearity for
all analytes was confirmed in the examined ranges
(R2≥0.9985 for AEA; R2≥0.9885 for PEA; R2≥0.9958 for
OEA). The validation parameters of the analytical method are
reported in the Supplementary methods.
Cytokine Analysis
Serum levels of IFN-γ, TNF-α, and IL-17 were measured by
enzyme-linked immunosorbent assays using predesigned kits
from R&D Systems (DuoSet; R&D systems, Minneapolis,
MN, USA), according to the manufacturer’s instructions.
Briefly, microtiter plates (Nunc, U16; Maxisorp, Vedbaek,
Denmark) were coated with monoclonal capture antibody (an-
tihuman IFN-γ, TNF-α, or IL-17) and incubated at 4 °C over-
night. The plates were then washed and subsequently incubat-
ed for 2 h with serum. The biotinylated detection antibodywas
then added and incubated for 2 h, followed by an incubation
for 20 min at room temperature with streptavidin–horseradish
peroxidase conjugate and the chromogenic substrate 3,3’,5,5’-
tetramethylbenzidine (Bangalore Genie, Bangalore, India).
The reaction was stopped using sulfuric acid (2 N) and the
optical density reading was taken at 450 nm using an Teknika
Microwell system, Reader 230 s (Organona, Eppelheim,
Germany). All the experiments were conducted in duplicates.
Standard curves were obtained using the standards provided
by the manufacturer, and the results are expressed as concen-
tration of cytokines (pg/ml).
Collection of Peripheral Blood Mononuclear Cells
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from patients with RR-MS at the study onset and
every 3 months after therapy started. Peripheral blood
was collected into ethylenediaminetetraacetic acid-
anticoagulant vacutainer tubes. PBMCs were isolated
by density-gradient centrifugation using Ficoll-Hypaque
(GE Healthcare, Little Chalfont, UK). Mononuclear cells
were harvested from the interface, washed 3 times with
saline, and subsequently washed with red blood cell
lysis buffer. Finally, the platelets were eliminated by
an additional wash and centrifugation at 200 × g for
10 min. PBMCs were stored as pellets at −80 °C for
mRNA isolation.
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Fatty Acid Amide Hydrolase and N-acylethanolamine-
hydrolyzing Acid Amidase mRNA Expression by PBMCs
mRNA extraction and quantitative reverse transcription poly-
merase chain reaction were performed as previously described
[34]. Briefly, total RNA was extracted using the TriPure re-
agent (Roche, Basel, Switzerland), according to the manufac-
turer’s instructions. cDNA was synthesized using a reverse
transcription kit (Promega, Leiden, the Netherlands) from
1 μg total RNA. Quantitative PCR was performed with a
STEP one PLUS instrument and software (Applied
Biosystems, Foster City, CA, USA). Data were normalized
to the 60S ribosomal protein L19 (RPL19) mRNA expression,
using the ΔΔCt method. Primer sequences were as follows:
RPL19 forward CACATCCACAAGCTGAAGGCA, reverse
CTTGCGTGCTTCCTTGGTCT; fatty acid amide hydrolase
(FAAH) forward CACACGCTGGTTCCCTTCTT, reverse
GGGTCCACGAAATCACCTTTGA; N-acylethanolamine-
h y d r o l y z i n g a c i d am i d a s e (NAAA ) f o rw a r d
AT G G A G C G T G G T T C C G A G T T , r e v e r s e
AGGCTGAGGTTTGCTTGTCCT.
Safety Assessment
Safety and tolerability were assessed by evaluating AEs and
clinical laboratory data (e.g., serum biochemistry and liver
enzymes). Blood samples for the evaluation of clinical labo-
ratory data were collected from all patients at each month of
the treatment.
Statistical Analysis
Data were analyzed with Generalized Linear Mixed Model
(GLMM) performed using SAS software version 9.2 (SAS
Institute, Cary, NC, USA). Statistical results were considered
statistically significant with p-values < 0.05. All variables
analyses were conducted using the unpaired t test, Mann–
Whitney test, χ2, or Fisher’s exact test when appropriate.
Statistical tests were 2-tailed, and Bonferroni correction was
applied to identify significant differences among groups.
Sample size was not calculated as the trial was intended as a
pilot study. The Spearman correlation coefficient was used for
the correlation between PEA plasma levels, NAE, and cyto-
kine serum levels.
Results
Demographics and baseline status showed no significant dif-
ferences between the groups (Table 1). Upon treatment, the
um-PEA-treated group perceived a significant improvement
in pain sensation at the IFN-β1a injection site after 6 and
12 months compared with the control group (Fig. 1A).
However, the improvement of pain sensation was not associ-
ated with a reduction in erythema width at the injection site
compared with study onset, and no significant differences
were observed between PEA-treated and placebo groups
(Fig. 1B).
PEA Improves Cognitive Domain of QoL
Without Affecting Clinical Disease Progression
The MSQoL-54 questionnaire evidenced that the um-PEA-
treated group experienced a significant improvement in cog-
nitive function, and change in health during the study, as
shown in Table 2. We did not find any significant difference
in the PASAT test between the PEA and placebo groups
(Table 3). The neurological examination showed no signifi-
cant progression of the disease in both groups, as evidenced
by the absence of significant changes in the EDSS scores over
the duration of the study (Table 4). We did not observe any
incidence of treatment-emergent AEs (i.e., AEs that occurred
after the first dose of the study drug). Similarly, we did not
observe any clinically significant abnormalities in laboratory
parameters in either group (data not shown). This shows the
good tolerability of um-PEA treatment in patients with MS.
PEATreatment Decreases Proinflammatory Cytokine
Serum Levels
Although all the patients were receiving IFN-β1a, we decided
to investigate the effects of um-PEA administration on the
inflammatory markers. Indeed, PEA is a known anti-
inflammatory bioactive lipid and its administration could have
an impact on inflammation. Therefore, we quantified the
Table 1 Baseline demographic and clinical characteristics
Characteristics Placebo (n= 14) um-PEA (n= 15)
Female, n (%) 9 (64) 6 (40)
Age (years) 28.93 ± 4.86 30.60 ± 7.60
EDSS score 2.3 ± 0.97 1.7 ± 0.9
VAS 58.5 ± 11.4 63.6 ± 18.7
Erythema (Ø) 23.1 ± 24.6 27.1 ± 22.7
MSQoL cognitive function 74.2 ± 9.6 71.4 ± 21.8
MSQoL change in health 42.0 ± 25.3 50.0 ± 16.9
Data are expressed as mean ± SD unless otherwise indicated
um-PEA=Ultramicronized palmitoylethanolamide; EDSS =Expanded
Disability Status Scale; VAS=Visual Analog Scale; MSQoL=Multiple
Sclerosis Quality of Life-54
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PEA Reduces Pain Perception Without a Reduction
of the Erythema at IFN-β1a Injection Site
serum levels of IFN-γ, IL-17, and TNF-α, 3 key cytokines
known to play a role in the physiopathology of MS. We ob-
served that um-PEA treatment induces a significant reduction
in the serum levels of these proinflammatory cytokines
(Fig. 2). Three months after the initiation of um-PEA treat-
ment, the levels of IFN-γ and IL-17 were significantly re-
duced compared with placebo (effects of treatment). This de-
crease was maintained throughout the study (impact of time)
(Fig. 2A, B). Similarly, TNF-α levels were significantly de-
creased by um-PEA after 6 and 12 months of treatment
(Fig. 2C). The levels of IFN-γ, TNF-α, and IL-17 in the group
receiving placebo remained relatively stable throughout the
duration of the study.
PEATreatment Increases Circulating NAE Levels
As the treated patients received oral um-PEA, we asked
whether this results in higher PEA plasma levels. As
shown in Fig. 3A, um-PEA administration results in an
increase of PEA plasma levels at month 3, which
remained relatively stable over the treatment period
and was significantly higher than the levels found in
the placebo group. Because the hydrolytic pathways of
PEA are shared by the other NAEs [2, 35], we next
sought to determine if treatment with oral um-PEA also
affected the levels of OEA and of the endocannabinoid
AEA. As illustrated in Fig. 3(B, C), um-PEA treatment
induced a significant increase in AEA and OEA plasma
levels after 3 months, which persisted throughout the
duration of the study. Of note, in the placebo group
NAE plasma levels were not significantly altered
throughout the study. Interestingly, when comparing the
NAE plasma levels, we found a strong positive correla-
tion between PEA and AEA plasma levels at 3, 6, 9, and
12 months of treatment (Table 5). OEA levels were also
correlated with PEA levels, although less markedly so.
FAAH and NAAA mRNA Expression in PBMCs
The inactivation of NAEs (AEA, OEA, and PEA) occurs es-
sentially by enzymatic hydrolysis by FAAH and NAAA
[35–39]. Thus, it is possible that um-PEA administration re-
duces the degradation of AEA and OEA by substrate compe-
tition. It is also conceivable that the increased levels of PEA
upon um-PEA administration have an impact on the expres-
sion of these two hydrolytic enzymes (Fig. 3A). Thus, our
next step was to investigate FAAH and NAAA mRNA ex-
pression in PBMCs. We conducted this analysis in PBMCs
because these cells are readily accessible and have been
shown to mirror CNS changes of NAEs levels [40]. At
1 month of treatment, FAAH and NAAA expression was sim-
ilar between the groups, as evidenced by a similar ΔCT (rel-
ative to the housekeeping gene RPL19) for the placebo and
PEA groups for each enzyme (Fig. 4A). However, we ob-
served a higher expression of NAAA than FAAH in each
group, as evidenced by the lower ΔCT of NAAA (Fig. 4A).
This higher expression of NAAA in PBMCs is reminiscent of
its strong expression in immune cells. At end of the study, the
data showed a moderate but significant difference in the ex-
pression of FAAH between the groups. Indeed, there was a
slight increase in FAAH expression over time in the placebo
group that was not present in the PEA-treated group (Fig. 4B).
As for NAAA expression there was no significant change in
expression over time or due to the treatment (Fig. 4C).
NAE Plasma Levels are Inversely Correlated
with Proinflammatory Cytokines
Finally, because proinflammatory cytokine levels were de-
creased while NAE levels were increased by um-PEA treat-
ment, we asked whether there was a correlation between the
Fig. 1 Ultramicronized palmitoylethanolamide (PEA) treatment reduces
pain perception but not erythema at interferon (IFN)-β1a injection site.
(A) Pain perception at the injection site of IFN-β1a was assessed using
the visual analog scale at month 1, and at 6 and 12 months after starting
PEA treatment (600 mg/day, p.o.). A significant effect of the treatment
was found both at 6 and 12 months. Data are expressed as mean± SEM;
*p< 0.05 versus the placebo group. (B) The diameter of the erythema
consequent to IFN-β1a injections was measured at 1 month, and after 6
and 12 months of PEA treatment. PEA had no effect on the erythema
width
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cytokine and bioactive lipid levels. We found, within 3 months
of treatment with um-PEA, an inverse correlation between PEA
and IFN-γ levels (Table 5). However, we did not find any cor-
relation between the levels of PEA and those of TNF-α or IL-
17. Interestingly, however, AEA plasma levels were inversely
correlated with IFN-γ, TNF-α, and IL-17 serum levels [AEA vs
IFN-γ: r=–0.7103 (p=0.0004); AEA vs TNF-α: r=–0.6042
(p=0.0048); AEA vs IL-17: r=–0.5506 (p=0.0012)]. We also
performed a hierarchical clustering analysis to investigate
whether we could distinguish the um-PEA-treated patients from
the placebo-treated patients only based on their cytokine
(IFN-γ, IL-17, TNF-α) serum levels. While at baseline no par-
ticular cluster was apparent, a progressive clusterization appears
over time (starting from month 3 to month 12). Actually, after
12 months of treatment, we found a nearly perfect clusterization
between the placebo and the um-PEA-treated group (Fig. 5),
thus further supporting the beneficial effects of um-PEA admin-
istration on the inflammatory tone of these patients.
Discussion
The results of the present study describe, for the first time, the
effects of oral um-PEA treatment as add-on therapy to
IFN-β1a in a cohort of patients with RR-MS.
Pain is an important component of MS, which, despite its
significant impact on patients’ QoL, is often neglected or
undertreated. Patients with MS present not only spontaneous
pain, but also several forms of evoked pain such as cutaneous
mechanical pain and cold hypersensitivity at the distal extrem-
ities [41, 42]. Promising results in the treatment of pain have
been reported for PEA in various clinical trials. In a pivotal
randomized, double-blind, placebo-controlled clinical trial of
636 patients with sciatic pain, a significant and clinically rel-
evant analgesic effect was documented for 300 mg and
600 mg PEA [43]. Hesselink and Hekker [44] also reported
a series of clinical cases describing the potential efficacy and
safety of um-PEA in the treatment of various syndromes
Table 3 Cognitive impairment assessed through paced auditory serial addition test (PASAT)
Measure Placebo treatment (n= 14) um-PEA treatment (n= 15)
1 month 6 months 12 months 1 month 6 months 12 months
PASAT 3" 35.5 ± 12.8 31.7 ± 17.8 41.1 ± 11.8 36.3 ± 13.6 38.7 ± 11.2 40.9 ± 10.9
PASAT 2" 34.5 ± 14.8 33.7 ± 18.3 36.5 ± 11.7 31.2 ± 12.7 36.9 ± 11.2 41.1 ± 11.2
Results are reported as mean ± SD. Differences between ultramicronized palmitoylethanolamide (um-PEA) and placebo groups were not significant
Table 2 Statistical analysis of quality of life; subscales of the Multiple Sclerosis Quality of Life-54 questionnaire
Subscales of MSQoL questionnaire Placebo treatment (n= 14) um-PEA treatment (n = 15) p-Value
1 month 6 months 12 months 1 month 6 months 12 months
Physical health 75.8 ± 20.8 71.3 ± 21.4 56.0 ± 15.6 74.6 ± 22.8 72.7 ± 19.5 62.9 ± 17.0
Role limitations due to
physical problems
48.1 ± 45.0 45.8 ± 38.0 57.0 ± 42.4 56.8 ± 38.2 50.0 ± 33.0 37.1 ± 39.5
Role limitation due to
emotional problems
53.8 ± 44.2 71.0 ± 34.7 63.4 ± 40.0 68.1 ± 34.8 50.4 ± 37.5 36.7 ± 34.9
Pain 63.7 ± 23.8 62.5 ± 25.3 61.6 ± 29.6 73.3 ± 20.1 66.3 ± 17.0 41.9 ± 27.0
Emotional well-being 55.7 ± 23.0 59.0 ± 20.8 52.0 ± 13.2 64.6 ± 4.2 57.2 ± 19.9 37.1 ± 21.4
Energy 51.9 ± 16.2 51.9 ± 13.8 52.0 ± 16.2 50.9 ± 18.7 47.0 ± 11.7 45.7 ± 15.1
Health perceptions 46.9 ± 8.1 44.8 ± 11.1 43.0 ± 8.2 43.9 ± 13.6 53.4 ± 12.5 40.0 ± 18.9
Cognitive function 74.2 ± 19.7 63.7 ± 16.4 52.0 ± 21.5 71.4 ± 21.9 50.8 ± 26.7 51.4 ± 22.7 0.0065
Social function 77.4 ± 14.7 77.0 ± 17.3 57.6 ± 24.9 69.5 ± 15.7 72.5 ± 17.9 58.9 ± 20.0
Health distress 51.6 ± 10.0 51.8 ± 10.7 49.2 ± 13.0 46.7 ± 0.0 41.3 ± 12.4 42.8 ± 15.3
Sexual function 90.8 ± 23.1 87.8 ± 24.7 77.2 ± 25.6 83.0 ± 5.8 92.3 ± 12.7 65.8 ± 28.2
Sexual satisfaction 65.8 ± 26.3 75.0 ± 28.0 74.0 ± 3.2 74.6 ± 25.4 75.0 ± 23.2 60.7 ± 19.0
Change in health 41.9 ± 25.3 58.3 ± 28.0 49.5 ± 35.0 49.6 ± 16.9 62.5 ± 18.9 31.5 ± 17.5 0.0396
Overall quality of life 50.8 ± 20.4 58.5 ± 18.3 46.7 ± 17.4 56.2 ± 16.6 46.3 ± 8.3 41.8 ± 14.2
Results are reported as mean ± SD
um-PEA= ultramicronized palmitoylethanolamide
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associated with chronic pain. In the present study, patients
treated with 600 mg um-PEA perceived an improvement in
pain sensation at the injection site of IFN-β1a. In addition to
pain, a common adverse effect of IFN-β1a therapy is the
erythema developing at the injection site. This reaction is cur-
rently thought to represent a local inflammatory response to
the injected drug, which is influenced by the injection path and
depth. This is consistent with the observation that skin reac-
tion is more likely to occur after injection in the arms or thighs,
and less frequently in areas with a higher proportion of sub-
cutaneous fat (e.g., abdomen or buttocks). Our analysis
Table 4 Expanded Disability Status Scale
Time Placebo treatment (n = 14) um-PEA treatment (n= 15)
1 month 2.3 ± 1.0 1.7 ± 0.9
3 months 2.2 ± 1.0 1.5 ± 0.9
6 months 2.3 ± 0.9 1.6 ± 0.8
9 months 2.4 ± 1.0 1.6 ± 0.8
12 months 2.5 ± 1.0 1.8 ± 1.2
Results are reported as mean ± SD
um-PEA= ultramicronized palmitoylethanolamide
Fig. 2 Ultramicronized palmitoylethanolamide (PEA) treatment reduces
proinflammatory cytokine serum levels. (A) Interferon (IFN)-γ, (B)
interleukin (IL)-17, and (C) tumor necrosis factor (TNF)-α serum levels
were measured by enzyme-linked immunosorbent assay at 1 month, and
after 3, 6, and 12 months of treatment with either placebo or um-PEA
(600 mg/day, p.o.). Similar cytokine levels between groups were found at
1 month, whereas at the subsequent time points PEA treatment reduced
the cytokine levels compared with the placebo group. Data are expressed
as mean± SEM; ***p< 0.001, **p < 0.01, *p< 0.05 versus the placebo
group
Fig. 3 Ultramicronized palmitoylethanolamide (PEA) treatment
increases plasma N-acylethanolamine levels. (A) PEA, (B) anandamide
(AEA), and (C) oleoylethanolamide (OEA) plasma levels were measured
by ultra performance liquid chromatography–mass spectrometry at
1 month, and after 3, 6, and 12 months of treatment with either placebo
or um-PEA (600 mg/day, p.o.). At treatment onset, similar levels were
found between the 2 treatment groups. After 3 months of treatment PEA,
AEA, and OEA levels were increased and remained higher for the
duration of the study. Data are expressed as mean ± SEM; ***p < 0.001,
**p< 0.01 versus the placebo group
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showed that, despite the reduced circulating cytokine levels,
the treatment with um-PEAwas not associated with a decrease
of the erythema at the injection site (abdomen and arms).
However, this might be owing to the fact that erythema is a
highly local reaction to injection that might better respond to
local administration of um-PEA.
QoL is a crucial element for patients living with MS.
Although the PASAT test did not show any improvement,
we found a positive effect of PEA treatment in the cognitive
function and health in theMSQoL questionnaire. This result is
in line with recent preclinical studies, showing that NAEs may
exert a beneficial effect following cognitive impairments
[45–47].
Unfortunately, the relatively small sample size of this
study did not allow us to assess the relationship be-
tween clinical disease activity measures and magnetic
resonance imaging. Nevertheless, we showed that PEA
treatment reduces IL-17 levels in patients with RR-MS
treated with IFN-β1a. This is significant as IL-17 me-
diates the inflammatory response in MS by controlling
the recruitment of immune cells and by regulating the
production of proinflammatory cytokines [48, 49].
Indeed, IL-17 induces the expression of TNF-α and
chemokines, attracts neutrophils, and enhances the mat-
uration of dendritic cells [50, 51]. Consistent with the
reduced IL-17 serum levels in the um-PEA-treated
group, we also found reduced TNF-α serum levels.
Importantly, this effect is obtained under IFN-β1a treat-
ment, which per se reduces the proinflammatory cyto-
kine serum levels in MS [52–54]. Inflammatory media-
tors, such as IFN-γ and TNF-α are known key contrib-
utors to the induction and maintenance of autoimmune
diseases [55–58]. However, although there is a vast
literature regarding the anti-inflammatory effects of
PEA in murine models, our study is the first to show
the ability of this bioactive lipid to reduce the proin-
flammatory cytokine profile in RR-MS.
We also found in this study that PEA levels are significantly
correlated with AEA and OEA levels. It remains to be deter-
mined whether this is due to competition for their hydrolysis or
to changes in the expression of the hydrolytic enzymes, or both.
Here we did not find any strong effect of um-PEA treatment on
NAAA mRNA expression in PBMCs. However, after a year of
treatment, PEA prevented the IFN-β1a-induced increase in
FAAH mRNA expression (Fig. 4B). This is important as it
was shown in human PBMCs that FAAH mRNA expression
Table 5 Correlation between palmitoylethanolamide (PEA) plasma
levels and N-acylethanolamine and cytokine serum levels
Time AEA OEA IFN-γ IL-17 TNF-α
3 months 0.734*** 0.5526** –0.6565*** –0.2547 0.1265
6 months 0.7504*** 0.4646* –0.5663** –0.1829 –0.1856
9 months 0.6481*** 0.4117* – – –
12 months 0.6882*** 0.6421** –0.6461** –0.2526 –0.3813
Nonparametric correlation between PEA levels and the levels of ananda-
mide (AEA) and oleoylethanolamide (OEA). Nonparametric correlation
between PEA plasma levels and the three cytokines quantified [interferon
(IFN)-γ, interleukin (IL)-17, and tumor necrosis factor (TNF)-α]
*p< 0.05; **p < 0.01; ***p < 0.001
Fig. 4 mRNA expression of the hydrolytic enzymes of N-
acylethanolamines, fatty acid amide hydrolase (FAAH) and N-
acylethanolamine- hydrolyzing acid amidase (NAAA) in peripheral
blood mononuclear cells (PBMCs). FAAH and NAAA mRNA expres-
sion in PBMCs was measured by quantitative reverse transcription using
RPL19 as housekeeping gene. (A) Expression of FAAH and NAAA at
1 month of treatment showing a higher expression of NAAA than FAAH,
as evidenced by the smaller ΔCt numbers (the smaller the ΔCt number
the higher the expression). (B) FAAH and (C) NAAAmRNA expression
during the study. Data are expressed as mean ± SEM versus the placebo
group. *p< 0.05 versus the placebo group
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correlates with protein expression and activity [59, 60]. In
fact, here we found that IFN-β1a treatment results in
decreased AEA levels after 12 months of treatment
[BIFN-β1a + placebo group^; 2-way analysis of variance
followed by the Bonferroni post-test (p< 0.01 for 12 months
vs 1 month)]. However, the fact that AEA and OEA levels
are already increased after 3 months of um-PEA treatment
might point towards a competition of AEA and OEA with
PEA for their hydrolysis, as previously demonstrated in
other settings.
The fact that oral administration of um-PEA not only
results in increased plasma levels of PEA, but also of other
NAEs is interesting in terms of potential synergistic effects,
as the NAEs do not all share the same molecular targets.
Indeed, most of the effects of PEA on inflammation and pain
are mediated by PPAR-α [5, 11, 13, 61], whereas AEA
mainly acts by activating cannabinoid receptors 1 and 2
[62, 63], and vanilloid (transient receptor potential vanilloid
1) receptors [64–66], and OEA by activating G protein-
coupled receptor 119 and PPAR-α [67, 68]. Thus, the effects
observed here upon um-PEA administration can be due to
PEA activating its molecular targets, and also to PEA favor-
ing the actions of other NAEs (e.g., AEA and OEA). Indeed,
anti-inflammatory, neuroprotective, and analgesic effects have
been reported for AEA and OEA in several preclinical
models [69–73].
In conclusion, although the sample size is relatively small
and the exact mechanisms explaining the effects of um-PEA
are yet to be determined, we show here that oral
administration of um-PEA as an add-on therapy in patients
with RR-MS provides beneficial effects in terms of reduced
circulating proinflammatory cytokines, pain sensation, and
increased NAE levels.
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